Everything above comes from Oaktree Acquisition Corp. III Life Sciences’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Not reported by this filer: Total Revenue, Cost of Revenue, Gross Profit, R&D Expense, SG&A Expense, Total Operating Expenses, Interest Expense, Income Tax Expense, Profit per share, Shares outstanding, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Inventory, Receivables, Long-term Debt (noncurrent), Long-term Debt (current), Short-term Borrowings, Borrowings (total), Operating Lease (current), Operating Lease (noncurrent), Operating Lease (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Capital Expenditures, Dividends paid, Stock-Based Compensation, Depreciation & Amortization, Depreciation, Amortization of Intangibles, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.